Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
Jin Liu, Xiaoxia Hu, Yanchun Jia, Jin Lu, Jae Hoon Lee, Kihyun Kım, Wen-Ming Chen, Aijun Liu, Yang Liu, Qi Chen, Chunyang Zhang, Cheolwon Suh, Min Kyoung Kim, Fan Zhou, Wee Joo Chng, Shaji Kumar, Brian G.M. Durie, Jian Hou, Weijun Fu, Juan Du
Abstract
Immunoglobulin D (IgD) myeloma is a rare isotype that comprises 1-2% of multiple myeloma (MM) patients [1-3], which has significantly inferior survival for a median overall survival (OS) between 13 and 21 months
Topics & Concepts
Multiple myelomaImmunoglobulin DMedicineInternal medicineOncologyHematologyMyeloma proteinCohortImmunologyAntibodyB cellMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisAmyloidosis: Diagnosis, Treatment, Outcomes